Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2004

View Archived Issues

Update on Riquent development program

Nobilon and BioDiem enter into flu vaccine licensing agreement

Non-approvable letter for Extina

Pharming to seek GRAS registration of recombinant human lactoferrin

Boston Scientific exercises right to exclusive paclitaxel license

Protalex pursues approval of PRTX-100 for pemphigus

Zambon forms Indian strategic partnership with Zydus Cadila

Vfend receives Canadian approval

Dainippon Pharmaceutical and Sumitomo Pharmaceuticals to merge

Antiproliferative effects of black tea polyphenols

Neuroprotective effects of levodopa and adenosine A2A receptor agonist

alpha-Glucosidase inhibitors from Hyssopus officinalis

Researchers at Pfizer describe CRF-1 receptor antagonists

Monoclonal antibodies targeting IGF-1R prepared by Roche scientists

GlaxoSmithKline claims antibacterial agents

Hypoxia inducible factor-1 (HIF-1) inhibitors described in a patent

Novel antimicrobial agents in early development at Aventis

Ivax claims oral formulations of cladribine

A new series of hydrazone derivatives patented by Daiichi

Clinical data confirm the efficacy and safety of natalizumab in Crohn's disease

One-year efficacy and safety of ABT-578-eluting stents in de novo coronary lesions

New data on the efficacy of CETP inhibitors in the treatment of dyslipidemia / News in Context

GISSI Heart Failure trial to assess n-3 polyunsaturated fatty acids, rosuvastatin

AVE-7688 provides renal protection in diabetes model

RSD-1235 induces cardioversion in atrial fibrillation model

Potassium-competitive gastric acid blocker shows prolonged effect in rat model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...